A potent inhibitor of ROCK-II, PRK-2, MSK1, and MAPKAP-K1b with IC50 values of 1.9, 4, 5, and 15 µM, respectively; has been shown to reduce blood vessel constriction, decreases pulmonary arterial pressure, inhibit tumor angiogenesis, and improve insulin signaling in a diabetic rat model; drug forms are marketed for the treatment of pulmonary arterial hypertension and stable angina.